Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc announces FDA approval of BRAVECTO

Tuesday, 20 May 2014 08:00am EDT 

Merck & Co Inc:U.S.FDA's approval of BRAVECTO chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).BRAVECTO is first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose.BRAVECTO also is effective for eight weeks against Amblyomma americanum ticks.Active substance of BRAVECTO, fluralaner, new ectoparasiticide belonging to isoxazoline group, is systemically active against fleas and ticks.Product can be used as part of treatment strategy for control of Flea Allergy Dermatitis (FAD) as a direct result of eliminating flea infestations. 

Company Quote

0.32 +0.56%
26 Dec 2014